Search

Now showing items 1-5 of 5

Metronomic chemotherapy with daily, oral etoposide plus bevacizumab for recurrent malignant glioma: a phase II study.

Bigner, DD; Desjardins, A; Friedman, AH; Friedman, HS; Gururangan, Sridharan; Herndon, James Emmett II; Marcello, JE; ... (13 authors) (Br J Cancer, 2009-12-15)

BACKGROUND: We evaluated bevacizumab with metronomic etoposide among recurrent malignant glioma patients in a phase 2, open-label trial. METHODS: A total of 59 patients, including 27 with glioblastoma (GBM) and 32 with grade ...

Serial dilution curve: a new method for analysis of reverse phase protein array data.

Wei, Qingyi; Zhang, Li; Mao, Li; Liu, Wenbin; Mills, Gordon B; Coombes, Kevin (Bioinformatics (Oxford, England), 2009-03)

Reverse phase protein arrays (RPPAs) are a powerful high-throughput tool for measuring protein concentrations in a large number of samples. In RPPA technology, the original samples are often diluted successively multiple ...

Polymorphisms of TGFB1 and VEGF genes and survival of patients with gastric cancer.

Wei, Qingyi; Guan, Xiaoxiang; Zhao, Hui; Niu, Jiangong; Tan, Dongfeng; Ajani, Jaffer A (Journal of experimental & clinical cancer research : CR, 2009-06-30)

Some TGFB1 and VEGF polymorphisms are believed to be functional. Given that these genes are involved in tumor growth and progression including angiogenesis, dissemination, and invasiveness, we hypothesized that ...

The VEGF -634G>C promoter polymorphism is associated with risk of gastric cancer.

Wei, Qingyi; Guan, Xiaoxiang; Zhao, Hui; Niu, Jiangong; Tang, Dongfeng; Ajani, Jaffer A (BMC gastroenterology, 2009-10-16)

Both TGF-beta1 and VEGF play a critic role in the multiple-step process of tumorgenesis of gastric cancer. Single nucleotide polymorphisms (SNPs) of the TGFB1 and VEGF genes have been associated with risk and progression ...

MYC activity mitigates response to rapamycin in prostate cancer through eukaryotic initiation factor 4E-binding protein 1-mediated inhibition of autophagy.

Balakumaran, BS; Febbo, PG; Foye, A; Glover, W; Hahn, WC; Hsu, DS; Leung, JY; ... (10 authors) (Cancer Res, 2009-10-01)

Loss of PTEN and activation of phosphoinositide 3-kinase are commonly observed in advanced prostate cancer. Inhibition of mammalian target of rapamycin (mTOR), a downstream target of phosphoinositide 3-kinase signaling, ...